Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: Reversal with rosiglitazone

Journal of Molecular and Cellular Cardiology

Volumn 35, Issue 4, 2003, Pages 417-419

  Verma, Subodh ^a   Wang, Chao Hung ^a   Weisel, Richard D ^a   Badiwala, Mitesh V ^a   Li, Shu Hong ^a   Fedak, Paul W M ^a   Li, Ren Ke ^a   Mickle, Donald A G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Atherosclerosis; C reactive protein; Endothelial cells; Hyperglycemia; Rosiglitazone

Indexed keywords

C REACTIVE PROTEIN; ROSIGLITAZONE;

ARTICLE; ATHEROGENESIS; CELL ACTIVATION; DRUG EFFECT; DRUG POTENTIATION; ENDOTHELIUM CELL; EVALUATION; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; INCUBATION TIME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; UPREGULATION;

EID: 0037383144     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2828(03)00042-7     Document Type: Article

References (10)

1. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J M. 347:2002;1557-1565.
2. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J M. 342:2000;836-843.
3. Verma S., Li S.H., Badiwala M.V., Weisel R.D., Fedak P.W.M., Li R.K., et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 105:2002;1890-1896.
4. Pasceri V., Chang J., Willerson J.T., Yeh E.T. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 103:2001;2531-2534.
5. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 102:2000;2165-2168.
6. Yeh E.T., Anderson H.V., Pasceri V., Willerson J.T. C-reactive protein: linking inflammation to cardiovascular complications. Circulation. 104:2001;974-975.
7. Verma S., Wang C.H., Li S.H., Dumont A.S., Fedak P.W.M., Badiwala M.V., et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 106:2002;913-919.
8. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation. 105:2002;1135-1143.
9. Woollard K.J., Phillips D.C., Griffiths H.R. Direct modulatory effect of C-reactive protein on primary human monocyte adhesion to human endothelial cells. Clin Exp Immunol. 130:2002;256-262.
10. Barbier O., Torra I.P., Duguay Y., Blanquart C., Fruchart J.C., Glineur C., et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 22:2002;717-726.